Return on equity (ROE) is the profit a company earns for every dollar of shareholder money invested in it, shown as a percentage. It is net income divided by shareholder equity, and the table shows both amounts: the profit earned and the equity it was earned on. A higher ROE means more profit per dollar of equity, but ROE also rises when equity shrinks through buybacks, dividends or losses, and it has no meaning for a company with negative equity. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.
Tango Therapeutics, Inc. roe for the quarter ending 2026-06-30 was -12.08%, a change of 95.79% year-over-year.
Tango Therapeutics, Inc. roe for the quarter ending 2026-03-31 was -27.39%, a change of 51.93% year-over-year.
Tango Therapeutics, Inc. roe for the quarter ending 2025-12-31 was -29.35%, a change of 35.96% year-over-year.
Tango Therapeutics, Inc. roe for the quarter ending 2025-09-30 was -62.81%, a change of -8.97% year-over-year.
Tango Therapeutics, Inc. roe for fiscal 2025 was -29.35%, a change of 35.96% from fiscal 2024.
Tango Therapeutics, Inc. roe for fiscal 2024 was -65.31%, a change of -25.11% from fiscal 2023.
Tango Therapeutics, Inc. roe for fiscal 2023 was -40.20%, a change of 3.16% from fiscal 2022.
Tango Therapeutics, Inc. roe for fiscal 2022 was -43.36%, a change of -26.47% from fiscal 2021.